TriGemX Bio, a biotechnology firm developing elismetrep for migraine treatment, will go public on Nasdaq under the ticker TGEM following a definitive merger agreement with TCGX Acquisition Corp. (NASDAQ: TCGX). The transaction aims to secure approximately $246 million in gross proceeds to fund clinical development.

The combined entity, to be named TriGemX Bio, Inc., expects to receive total gross proceeds of approximately $246 million prior to transaction costs and assuming no redemptions by public shareholders of the SPAC. This capital structure relies on two primary components: the trust account balance of the special purpose acquisition company and a concurrent private investment.

Funding structure and investor base

The capital infusion is split between existing SPAC assets and new institutional investment. The funding breakdown is as follows:

The $160 million Private Investment in Public Equity (PIPE) financing involves a group of premier healthcare investors. Participating firms include TCGX, Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital, and Vianti Capital, alongside other leading healthcare investors. Jefferies and TD Cowen acted as joint lead placement agents for the PIPE, while Cantor and LifeSci Capital served as additional placement agents.

Transaction details and valuation

TCGX Acquisition Corp. is a special purpose acquisition company sponsored by TCGX. Upon closing, the combined company will operate as a publicly traded entity focused on advancing elismetrep, a potential first-in-class treatment for migraine. The deal execution marks the transition from private development status to public market listing.

Assuming no redemptions by TCGX Acquisition Corp.’s public shareholders, the Combined Company is expected to have a post-transaction equity value of approximately $600 million at closing. TriGemX Bio shareholders will not receive any cash proceeds as part of the transaction and will roll 100% of their equity into the Combined Company. The transaction is subject to shareholder approval and customary closing conditions, with completion expected in the first quarter of 2027.

Use of proceeds and clinical roadmap

Net proceeds from the transaction are expected to provide the Combined Company with the capital needed to advance its pipeline. Key allocations include:

• Completing ongoing elismetrep Phase 3 clinical trials for acute migraine treatment and submitting a New Drug Application (NDA) for this indication.
• Completing a clinical trial of elismetrep in migraine prevention using a distinct dose and formulation.
• Enabling key commercial readiness activities as the Combined Company prepares for a potential U.S. launch.

Jeff Goater, CEO of TriGemX Bio, stated that the anticipated proceeds position the company to fully fund Phase 3 development and undertake commercial readiness activities. Elismetrep is an investigational oral TRPM8 channel blocker shown to be well-tolerated in Phase 2b trials, with results from the first Phase 3 trial anticipated in mid-2027.

What the numbers show

The PIPE financing constitutes 65% of the total expected gross proceeds ($160 million out of $246 million), indicating that new institutional capital significantly outweighs the retained trust account value ($86 million). This heavy reliance on concurrent equity investment suggests strong immediate institutional backing for the pipeline asset, reducing dependency on the variable redemption rates typical of SPAC transactions. The implied post-money valuation of $600 million against $246 million in gross proceeds suggests a significant premium over the pre-money valuation, reflecting investor confidence in the commercial potential of elismetrep.